Tekcapital portfolio company Belluscura (LON:BELL) have provided an update on the roll-out of their portable oxygen devices, alongside the announcement of a distribution agreement with a leading US supplier. Tekcapital has a 14% stake in AIM-listed Belluscura, currently valued in the region of £11m.
Download your research report now for instant access.
Please read the High Net Worth Individual Statement or Sophisticated Investor Statement before downloading this guide.
Risk warning: Please click here to read the full risk warning.
Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Kemeny Capital is targeted at investors who are sufficiently sophisticated to understand these risks. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
This page has been approved as a financial promotion by Kemeny Capital, which is authorised and regulated by the Financial Conduct Authority (No. 941978). Investments found on the Kemeny Capital website are not available or directed at the general public.
Kemeny Capital is exclusively aimed at UK resident persons who are required to self-certify as either a Sophisticated Investor or High Net Worth Individual.
Kemeny Capital does not provide advice on Investments, tax or legal affairs. Kemeny Capital Ltd is Authorised and Regulated by the Financial Conduct Authority, FCA Register Number 941978. Kemeny Capital, 71-75 Shelton Street, London, Registered in England, Company Number 12871856.